Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
CINC CinCor Pharma
28.930+0.030+0.10%
Close
01/31 16:00 ET
High
29.055
Open
28.910
Turnover
12.95M
Low
28.840
Pre Close
28.900
Volume
447.47K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CINC, ALBO, PAYA, QUMU
NEW YORK, Jan. 29, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary
CinCor Pharma, Inc. (NASDAQ:CINC) Receives Consensus Rating of "Moderate Buy" From Brokerages
Shares of CinCor Pharma, Inc. (NASDAQ:CINC – Get Rating) have received an average rating of "Moderate Buy" from the eight analysts that are currently covering the stock, Marketbeat Ratings reports.
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - LBC, ALBO, CINC, LMST
NEW YORK, Jan.
Moore Kuehn Encourages GMGI, CINC, ALBO, and PAYA Investors to Contact Law Firm
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CINC, ALBO, PAYA
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger ALBO, CINC, IMRA
CINCOR PHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CinCor Pharma, Inc. - CINC
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of CinCor Pharma, I
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CNCE, CINC, ALBO
SHAREHOLDER ALERT: Weiss Law Reminds LPTX, CNCE, ALBO, and CINC Shareholders About Its Ongoing Investigations
Biotech IPO Window to Reopen in 2023 Following Muted Activity in 2022, Oppenheimer Says
03:09 PM EST, 01/23/2023 (MT Newswires) -- Initial public offering activity in the biotechnology industry was "substantially lower" last year than in 2021 as private companies awaited better market co
Company Overview
More
CinCor Pharma, Inc. operates as a clinical-stage biopharmaceutical company focused on developing its clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. The firm is developing CIN-107 for the treatment of multiple diseases where aldosterone plays a significant role in disease pathophysiology, including hypertension and primary aldosteronism, as well as its utility in ameliorating complications of chronic kidney disease. The company was founded by Jon Isaacsohn and Catherine Pearce on March 28, 2018 and is headquartered in Waltham, MA.
CEO： Mr. Marc de Garidel
Market： NASDAQ
Listing Date： 01/07/2022
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet